{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T05:52:18Z","timestamp":1775627538009,"version":"3.50.1"},"reference-count":107,"publisher":"Bentham Science Publishers Ltd.","issue":"10","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Dementia with Lewy Bodies is a neurodegenerative disorder characterised by abnormal \u03b1-\nSynuclein aggregate accumulation in Lewy Bodies and Lewy Neurites and the most common form of\ndementia after Alzheimer\u2019s disease. The presynaptic protein alpha-synuclein (\u03b1-Syn) regulates synaptic\nvesicle trafficking and the subsequent release of neurotransmitters in the brain. These aggregates\ngo through a number of crucial stages, such as aggregation, oligomerization, and fibrillation.\nTreatment of this disorder is generally symptomatic. This necessitates the development of cuttingedge\ntherapeutic approaches that can either stop or change the course of the diseases. Many studies\nhave shown that \u03b1-synuclein is a significant therapeutic target and that inhibiting \u03b1-synuclein aggregation,\noligomerization, and fibrillation is an important disease-modifying strategy. Since \u03b1-syn is a\ndefining feature of Parkinson\u2019s disease, the current review provides an overview of plant phytochemicals\nand synthetic heterocyclic compounds that target \u03b1-syn in Parkinson's disease in order to develop\nnew drugs for Dementia with Lewy Bodies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573406419666230718121644","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T06:35:25Z","timestamp":1689748525000},"page":"946-959","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Unique Perspective on Lead Compounds for Dementia with the Lewy\nBody"],"prefix":"10.2174","volume":"19","author":[{"given":"Menaka","family":"Subramani","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, C.L. Baid Metha College of Pharmacy, Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amuthalakshmi","family":"Sivaperuman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, C.L. Baid Metha College of Pharmacy, Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramalakshmi","family":"Natarajan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, C.L. Baid Metha College of Pharmacy, Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keerthana","family":"Dhinakaran","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, C.L. Baid Metha College of Pharmacy, Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S0140-6736(15)00462-6","volume":"386","author":"Walker Z.","year":"2015","unstructured":"Walker Z.; Possin K.L.; Boeve B.F.; Aarsland D.; Lewy body dementias. Lancet 2015,386(10004),1683-1697","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"Spillantini MG","year":"1997","unstructured":"Spillantini MG; Schmidt ML; Lee VMY; Trojanowski JQ; Jakes R; Goedert M; \u03b1-Synuclein in Lewy bodies. Nature 1997,388(6645),839-840","journal-title":"Nature"},{"key":"ref=3","unstructured":"Stanfordhealth care.. Cause of dementia with lewy bodies (DLB). Available from:"},{"key":"ref=4","unstructured":"National Institute on Aging. What is lewy body dementia? 2016. Available from:  (Accessed on October 6, 2016)"},{"key":"ref=5","unstructured":"2021. Available from:  (Accessed on April 30, 2021)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"17562864211057666","DOI":"10.1177\/17562864211057666","volume":"14","author":"Armstrong M.J.","year":"2021","unstructured":"Armstrong M.J.; Advances in dementia with Lewy bodies. Ther Adv Neurol Disord 2021,14,17562864211057666","journal-title":"Ther Adv Neurol Disord"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(19)30153-X","volume":"19","author":"Taylor J.P.","year":"2020","unstructured":"Taylor J.P.; McKeith I.G.; Burn D.J.; New evidence on the management of Lewy body dementia. Lancet Neurol 2020,19(2),157-169","journal-title":"Lancet Neurol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1017\/S0033291717003257","volume":"48","author":"Connors M.H.","year":"2018","unstructured":"Connors M.H.; Quinto L.; McKeith I.; Non-pharmacological interventions for Lewy body dementia: A systematic review. Psychol Med 2018,48(11),1749-1758","journal-title":"Psychol Med"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1176\/appi.ajp.2015.14121582","volume":"172","author":"Stinton C.","year":"2015","unstructured":"Stinton C.; McKeith I.; Taylor J.P.; Pharmacological management of lewy body dementia: A systematic review and meta-analysis. Am J Psychiatry 2015,172(8),731-742","journal-title":"Am J Psychiatry"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s004010100390","volume":"102","author":"Harding A.J.","year":"2001","unstructured":"Harding A.J.; Halliday G.M.; Cortical lewy body pathology in the diagnosis of dementia. Acta Neuropathol 2001,102(4),355-363","journal-title":"Acta Neuropathol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1212\/WNL.0b013e3181d55f61","volume":"74","author":"Klein J.C.","year":"2010","unstructured":"Klein J.C.; Eggers C.; Kalbe E.; Neurotransmitter changes in dementia with lewy bodies and parkinson disease dementia in vivo. Neurology 2010,74(11),885-892","journal-title":"Neurology"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-019-0306-8","volume":"14","author":"Outeiro T.F.","year":"2019","unstructured":"Outeiro T.F.; Koss D.J.; Erskine D.; Dementia with lewy bodies: An update and outlook. Mol Neurodegener 2019,14(1),5","journal-title":"Mol Neurodegener"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"McKeith I.G.","year":"2005","unstructured":"McKeith I.G.; Dickson D.W.; Lowe J.; Diagnosis and management of dementia with lewy bodies: Third report of the DLB consortium. Neurology 2005,65(12),1863-1872","journal-title":"Neurology"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"McKeith I.G.","year":"2017","unstructured":"McKeith I.G.; Boeve B.F.; Dickson D.W.; Diagnosis and management of dementia with lewy bodies. Neurology 2017,89(1),88-100","journal-title":"Neurology"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s40266-018-00636-7","volume":"36","author":"Hershey L.A.","year":"2019","unstructured":"Hershey L.A.; Coleman-Jackson R.; Pharmacological management of dementia with lewy bodies. Drugs Aging 2019,36(4),309-319","journal-title":"Drugs Aging"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.19052","volume":"13","author":"Yamada M.","year":"2020","unstructured":"Yamada M.; Komatsu J.; Nakamura K.; Diagnostic criteria for dementia with lewy bodies: Updates and future directions. J Mov Disord 2020,13(1),1-10","journal-title":"J Mov Disord"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11940-017-0478-x","volume":"19","author":"Tousi B.","year":"2017","unstructured":"Tousi B.; Diagnosis and management of cognitive and behavioral changes in dementia with lewy bodies. Curr Treat Options Neurol 2017,19(11),42","journal-title":"Curr Treat Options Neurol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1111\/jan.14932","volume":"77","author":"Bentley A.","year":"2021","unstructured":"Bentley A.; Morgan T.; Salifu Y.; Walshe C.; Exploring the experiences of living with Lewy body dementia: An integrative review. J Adv Nurs 2021,77(12),4632-4645","journal-title":"J Adv Nurs"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000515008","volume":"50","author":"Tsamakis K.","year":"2021","unstructured":"Tsamakis K.; Mueller C.; Challenges in predicting cognitive decline in dementia with lewybodies. Dement Geriatr Cogn Disord 2021,50(1),1-8","journal-title":"Dement Geriatr Cogn Disord"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40120-019-00154-7","volume":"8","author":"Tahami M.A.A.","year":"2019","unstructured":"Tahami M.A.A.; Meier G.; Perry R.; Joe D.; Burden of disease and current management of dementia with Lewy bodies: A literature review. Neurol Ther 2019,8(2),289-305","journal-title":"Neurol Ther"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1471-4159.2008.05612.x","volume":"107","author":"Kim C.","year":"2008","unstructured":"Kim C.; Lee S.J.; Controlling the mass action of \u03b1-synuclein in Parkinson\u2019s disease. J Neurochem 2008,107(2),303-316","journal-title":"J Neurochem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1212\/01.wnl.0000256715.13907.d3","volume":"68","author":"Lippa C.F.","year":"2007","unstructured":"Lippa C.F.; Duda J.E.; Grossman M.; DLB and PDD boundary issues: Diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007,68(11),812-819","journal-title":"Neurology"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.neuron.2011.08.033","volume":"72","author":"Volpicelli-Daley L.A.","year":"2011","unstructured":"Volpicelli-Daley L.A.; Luk K.C.; Patel T.P.; Exogenous \u03b1-synuclein fibrils induce lewy body pathology leading to synaptic dysfunction and neuron death. Neuron 2011,72(1),57-71","journal-title":"Neuron"},{"key":"ref=24","first-page":"879","volume":"152","author":"Baba M.","year":"1998","unstructured":"Baba M.; Nakajo S.; Tu P.H.; Aggregation of alpha-synuclein in lewy bodies of sporadic parkinson\u2019s disease and dementia with lewy bodies. Am J Pathol 1998,152(4),879-884","journal-title":"Am J Pathol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/jnc.13249","volume":"139","author":"Villar-Piqu\u00e9 A.","year":"2016","unstructured":"Villar-Piqu\u00e9 A.; Lopes da Fonseca T.; Outeiro T.F.; Structure, function and toxicity of alpha-synuclein: The bermuda triangle in synucleinopathies. J Neurochem 2016,139(1),240-255","journal-title":"J Neurochem"},{"key":"ref=26","first-page":"1","volume":"3","author":"Sode K.","year":"2006","unstructured":"Sode K.; Ochiai S.; Kobayashi N.; Usuzaka E.; Effect of reparation of repeat sequences in the human \u03b1-synuclein on fibrillation ability. Int J Biol Sci 2006,3(1),1-7","journal-title":"Int J Biol Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0047-6374(01)00283-4","volume":"122","author":"Rajagopalan S.","year":"2001","unstructured":"Rajagopalan S.; Andersen J.K.; Alpha synuclein aggregation: Is it the toxic gain of function responsible for neurodegeneration in parkinson\u2019s disease? Mech Ageing Dev 2001,122(14),1499-1510","journal-title":"Mech Ageing Dev"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"10005","DOI":"10.1021\/acs.jpcb.5b03760","volume":"119","author":"Atsmon-Raz Y.","year":"2015","unstructured":"Atsmon-Raz Y.; Miller Y.; A Proposed atomic structure of the self-assembly of the Non-Amyloid-\u03b2 Component of Human \u03b1-Synuclein as derived by computational tools. J Phys Chem B 2015,119(31),10005-10015","journal-title":"J Phys Chem B"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-020-00368-6","volume":"15","author":"Hijaz B.A.","year":"2020","unstructured":"Hijaz B.A.; Volpicelli-Daley L.A.; Initiation and propagation of \u03b1-synuclein aggregation in the nervous system. Mol Neurodegener 2020,15(1),19","journal-title":"Mol Neurodegener"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.plipres.2010.05.004","volume":"49","author":"Ruip\u00e9rez V.","year":"2010","unstructured":"Ruip\u00e9rez V.; Darios F.; Davletov B.; Alpha-synuclein, lipids and parkinson\u2019s disease. Prog Lipid Res 2010,49(4),420-428","journal-title":"Prog Lipid Res"},{"key":"ref=31","unstructured":"U.S. National Library of Medicine. Genetics home reference: SNCA. Available from:  (accessed on Nov14, 2013)"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"115640","DOI":"10.1016\/j.bmc.2020.115640","volume":"28","author":"Maqbool M.","year":"2020","unstructured":"Maqbool M.; Rajvansh R.; Srividya K.; Hoda N.; Deciphering the robustness of pyrazolo-pyridine carboxylate core structure-based compounds for inhibiting \u03b1-synuclein in transgenic C. elegans model of synucleinopathy. Bioorg Med Chem 2020,28(17),115640","journal-title":"Bioorg Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"10262","DOI":"10.1021\/jf101417w","volume":"58","author":"Chi Z.","year":"2010","unstructured":"Chi Z.; Liu R.; Teng Y.; Fang X.; Gao C.; Binding of oxytetracycline to bovine serum albumin: Spectroscopic and molecular modeling investigations. J Agric Food Chem 2010,58(18),10262-10269","journal-title":"J Agric Food Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1021\/ml500222g","volume":"5","author":"Sashidhara K.V.","year":"2014","unstructured":"Sashidhara K.V.; Modukuri R.K.; Jadiya P.; Discovery of 3-arylcoumarin-tetracyclic tacrine hybrids as multifunctional agents against parkinson\u2019s disease. ACS Med Chem Lett 2014,5(10),1099-1103","journal-title":"ACS Med Chem Lett"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0014-5793(98)01146-6","volume":"436","author":"Crowther R.A.","year":"1998","unstructured":"Crowther R.A.; Jakes R.; Spillantini M.G.; Goedert M.; Synthetic filaments assembled from C-terminally truncated \u03b1-synuclein. FEBS Lett 1998,436(3),309-312","journal-title":"FEBS Lett"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"168","DOI":"10.2174\/1389557514666140131111837","volume":"14","author":"Kumar R.","year":"2014","unstructured":"Kumar R.; Sirohi T.S.; Singh H.; 1,2,4-triazine analogs as novel class of therapeutic agents. Mini Rev Med Chem 2014,14(2),168-207","journal-title":"Mini Rev Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.neuint.2010.10.002","volume":"57","author":"Ansari N.","year":"2010","unstructured":"Ansari N.; Khodagholi F.; Ramin M.; Inhibition of LPS-induced apoptosis in differentiated-PC12 cells by new triazine derivatives through NF-\u03baB-mediated suppression of COX-2. Neurochem Int 2010,57(8),958-968","journal-title":"Neurochem Int"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"4224","DOI":"10.1016\/j.bmc.2010.04.097","volume":"18","author":"Irannejad H.","year":"2010","unstructured":"Irannejad H.; Amini M.; Khodagholi F.; Synthesis and in vitro evaluation of novel 1,2,4-triazine derivatives as neuroprotective agents. Bioorg Med Chem 2010,18(12),4224-4230","journal-title":"Bioorg Med Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ejmech.2017.04.064","volume":"136","author":"Jameel E.","year":"2017","unstructured":"Jameel E.; Meena P.; Maqbool M.; Rational design, synthesis and biological screening of triazine: Triazolopyrimidine hybrids as multitarget anti-Alzheimer agents. Eur J Med Chem 2017,136(136),36-51","journal-title":"Eur J Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.bioorg.2018.11.038","volume":"84","author":"Yazdani M.","year":"2019","unstructured":"Yazdani M.; Edraki N.; Badri R.; Khoshneviszadeh M.; Iraji A.; Firuzi O.; Multi-target inhibitors against alzheimer disease derived from 3-hydrazinyl 1,2,4-triazine scaffold containing pendant phenoxy methyl-1,2,3-triazole: Design, synthesis and biological evaluation. Bioorg Chem 2019,84,363-371","journal-title":"Bioorg Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s11030-019-09970-3","volume":"24","author":"Yazdani M.","year":"2020","unstructured":"Yazdani M.; Edraki N.; Badri R.; Khoshneviszadeh M.; Iraji A.; Firuzi O.; 5,6-Diphenyl triazine-thio methyl triazole hybrid as a new Alzheimer\u2019s disease modifying agents. Mol Divers 2020,24(3),641-654","journal-title":"Mol Divers"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"112705","DOI":"10.1016\/j.ejmech.2020.112705","volume":"207","author":"Maqbool M.","year":"2020","unstructured":"Maqbool M.; Gadhavi J.; Hivare P.; Gupta S.; Hoda N.; Diphenyl triazine hybrids inhibit \u03b1-synuclein fibrillogenesis: Design, synthesis and in vitro efficacy studies. Eur J Med Chem 2020,207,112705","journal-title":"Eur J Med Chem"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","volume":"125","author":"Wagner J.","year":"2013","unstructured":"Wagner J.; Ryazanov S.; Leonov A.; Anle138b: A novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and parkinson\u2019s disease. Acta Neuropathol 2013,125(6),795-813","journal-title":"Acta Neuropathol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00401-014-1265-3","volume":"127","author":"Levin J.","year":"2014","unstructured":"Levin J.; Schmidt F.; Boehm C.; The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathol 2014,127(5),779-780","journal-title":"Acta Neuropathol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1021\/acschemneuro.0c00252","volume":"11","author":"Ryan P.","year":"2020","unstructured":"Ryan P.; Xu M.; Jahan K.; Novel furan-2-yl-1H-pyrazoles possess inhibitory activity against \u03b1-synuclein aggregation. ACS Chem Neurosci 2020,11(15),2303-2315","journal-title":"ACS Chem Neurosci"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3390\/ijms18030478","volume":"18","author":"Pujols J.","year":"2017","unstructured":"Pujols J.; Pe\u00f1a-D\u00edaz S.; Conde-Gim\u00e9nez M.; High-throughput screening methodology to identify alpha: Synuclein aggregation inhibitors. Int J Mol Sci 2017,18(3),478","journal-title":"Int J Mol Sci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"10481","DOI":"10.1073\/pnas.1804198115","volume":"115","author":"Pujols J.","year":"2018","unstructured":"Pujols J.; Pe\u00f1a-D\u00edaz S.; L\u00e1zaro D.F.; Small molecule inhibits \u03b1-synuclein aggregation, disrupts amyloid fibrils, and prevents degeneration of dopaminergic neurons. Proc Natl Acad Sci 2018,115(41),10481-10486","journal-title":"Proc Natl Acad Sci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"105472","DOI":"10.1016\/j.bioorg.2021.105472","volume":"117","author":"Mah\u00eda A.","year":"2021","unstructured":"Mah\u00eda A.; Pe\u00f1a-D\u00edaz S.; Navarro S.; Design, synthesis and structure-activity evaluation of novel 2-pyridone-based inhibitors of \u03b1-synuclein aggregation with potentially improved BBB permeability. Bioorg Chem 2021,117,105472","journal-title":"Bioorg Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"14174","DOI":"10.1021\/acs.joc.0c01699","volume":"85","author":"Adolfsson D.E.","year":"2020","unstructured":"Adolfsson D.E.; Tyagi M.; Singh P.; Intramolecular Povarov reactions for the synthesis of chromenopyridine fused 2-Pyridone polyheterocycles binding to \u03b1-Synuclein and Amyloid-\u03b2 Fibrils. J Org Chem 2020,85(21),14174-14189","journal-title":"J Org Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3389\/fphar.2018.01555","volume":"9","author":"Javed H.","year":"2019","unstructured":"Javed H.; Nagoor M.M.F.; Azimullah S.; Adem A.; Sadek B.; Ojha S.K.; Plant extracts and phytochemicals target \u03b1-synuclein aggregation in Parkinson\u2019s disease models. Front Pharmacol 2019,9,1555","journal-title":"Front Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1016\/j.bmc.2012.06.023","volume":"20","author":"Yu L.","year":"2012","unstructured":"Yu L.; Cui J.; Padakanti P.K.; Synthesis and in vitro evaluation of \u03b1-synuclein ligands. Bioorg Med Chem 2012,20(15),4625-4634","journal-title":"Bioorg Med Chem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"6002","DOI":"10.1021\/acs.jmedchem.5b00571","volume":"58","author":"Chu W.","year":"2015","unstructured":"Chu W.; Zhou D.; Gaba V.; Design, synthesis, and characterization of 3-(benzylidene)indolin-2-one derivatives as ligands for \u03b1-synuclein fibrils. J Med Chem 2015,58(15),6002-6017","journal-title":"J Med Chem"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1016\/j.bmc.2019.05.032","volume":"27","author":"Liu H.","year":"2019","unstructured":"Liu H.; Chen L.; Zhou F.; Anti-oligomerization sheet molecules: Design, synthesis and evaluation of inhibitory activities against \u03b1-synuclein aggregation. Bioorg Med Chem 2019,27(14),3089-3096","journal-title":"Bioorg Med Chem"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.3390\/ijms21103561","volume":"21","author":"Kobayashi H.","year":"2020","unstructured":"Kobayashi H.; Murata M.; Kawanishi S.; Oikawa S.; Polyphenols with anti-amyloid \u03b2 aggregation show potential risk of toxicity via pro-oxidant properties. Int J Mol Sci 2020,21(10),3561","journal-title":"Int J Mol Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"115596","DOI":"10.1016\/j.bmc.2020.115596","volume":"28","author":"Chen L.","year":"2020","unstructured":"Chen L.; Huang G.L.; L\u00fc M.H.; Zhang Y.X.; Xu J.; Bai S.P.; Amide derivatives of Gallic acid: Design, synthesis and evaluation of inhibitory activities against in vitro \u03b1-synuclein aggregation. Bioorg Med Chem 2020,28(15),115596","journal-title":"Bioorg Med Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.bmc.2019.03.005","volume":"27","author":"Yang X.","year":"2019","unstructured":"Yang X.; Cai S.; Liu X.; Chen P.; Zhou J.; Zhang H.; Design, synthesis and biological evaluation of 2,5-dimethylfuran-3-carboxylic acid derivatives as potential IDO1 inhibitors. Bioorg Med Chem 2019,27(8),1605-1618","journal-title":"Bioorg Med Chem"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"E1817","DOI":"10.1073\/pnas.1305623110","volume":"110","author":"Decressac M.","year":"2013","unstructured":"Decressac M.; Mattsson B.; Weikop P.; Lundblad M.; Jakobsson J.; Bj\u00f6rklund A.; TFEB-mediated autophagy rescues midbrain dopamine neurons from \u03b1-synuclein toxicity. Proc Natl Acad Sci 2013,110(19),E1817-E1826","journal-title":"Proc Natl Acad Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1093\/brain\/awt131","volume":"136","author":"Xilouri M.","year":"2013","unstructured":"Xilouri M.; Brekk O.R.; Landeck N.; Boosting chaperone-mediated autophagy in vivo mitigates \u03b1-synuclein-induced neurodegeneration. Brain 2013,136(7),2130-2146","journal-title":"Brain"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.ymthe.2018.08.019","volume":"26","author":"Kantor B.","year":"2018","unstructured":"Kantor B.; Tagliafierro L.; Gu J.; Down regulation of SNCA expression by targeted editing of DNA methylation: A potential strategy for precision therapy in PD. Mol Ther 2018,26(11),2638-2649","journal-title":"Mol Ther"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.nbd.2019.01.004","volume":"125","author":"Zharikov A.","year":"2019","unstructured":"Zharikov A.; Bai Q.; De Miranda B.R.; Van Laar A.; Greenamyre J.T.; Burton E.A.; Long-term RNAi knockdown of \u03b1-synuclein in the adult rat substantia nigra without neurodegeneration. Neurobiol Dis 2019,125,146-153","journal-title":"Neurobiol Dis"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"17579","DOI":"10.1074\/jbc.M112.434787","volume":"288","author":"Shaltiel-Karyo R.","year":"2013","unstructured":"Shaltiel-Karyo R.; Frenkel-Pinter M.; Rockenstein E.; A blood-brain barrier (BBB) disrupter is also a potent \u03b1-synuclein (\u03b1-syn) aggregation inhibitor: A novel dual mechanism of mannitol for the treatment of Parkinson disease (PD). J Biol Chem 2013,288(24),17579-17588","journal-title":"J Biol Chem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"e11101","DOI":"10.1371\/journal.pone.0011101","volume":"5","author":"Scherzer-Attali R.","year":"2010","unstructured":"Scherzer-Attali R.; Pellarin R.; Convertino M.; Complete phenotypic recovery of an Alzheimer\u2019s disease model by a quinone-tryptophan hybrid aggregation inhibitor. PLoS One 2010,5(6),e11101","journal-title":"PLoS One"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1002\/prot.24080","volume":"80","author":"Scherzer-Attali R.","year":"2012","unstructured":"Scherzer-Attali R.; Shaltiel-Karyo R.; Adalist Y.; Segal D.; Gazit E.; Generic inhibition of amyloidogenic proteins by two naphthoquinone-tryptophan hybrid molecules. Proteins 2012,80(8),1962-1973","journal-title":"Proteins"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1002\/1521-3773(20020715)41:14<2596:AID-ANIE2596>3.0.CO;2-4","volume":"41","author":"Rostovtsev V.V.","year":"2002","unstructured":"Rostovtsev V.V.; Green L.G.; Fokin V.V.; Sharpless K.B.; A stepwise huisgen cycloaddition process: Copper(I)-catalyzed regioselective \u201cligation\u201d of azides and terminal alkynes. Angew Chem Int Ed 2002,41(14),2596-2599","journal-title":"Angew Chem Int Ed"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1021\/jo011148j","volume":"67","author":"Torn\u00f8e C.W.","year":"2002","unstructured":"Torn\u00f8e C.W.; Christensen C.; Meldal M.; Peptidotriazoles on solid phase: [1,2,3]-triazoles by regiospecific copper(i)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J Org Chem 2002,67(9),3057-3064","journal-title":"J Org Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3389\/fmolb.2019.00016","volume":"6","author":"Paul A.","year":"2019","unstructured":"Paul A.; Zhang B.D.; Mohapatra S.; Novel mannitol-based small molecules for inhibiting aggregation of \u03b1-synuclein amyloids in parkinson\u2019s disease. Front Mol Biosci 2019,6(16),16","journal-title":"Front Mol Biosci"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3389\/fnmol.2019.00306","volume":"12","author":"Pe\u00f1a-D\u00edaz S.","year":"2019","unstructured":"Pe\u00f1a-D\u00edaz S.; Pujols J.; Conde-Gim\u00e9nez M.; ZPD-2, a small compound that inhibits alpha-synuclein amyloid aggregation and its seeded polymerization. Front Mol Neurosci 2019,12(306),306","journal-title":"Front Mol Neurosci"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"588947","DOI":"10.3389\/fbioe.2020.588947","volume":"8","author":"Pe\u00f1a-D\u00edaz S.","year":"2020","unstructured":"Pe\u00f1a-D\u00edaz S.; Pujols J.; Pinheiro F.; Inhibition of \u03b1-synuclein aggregation and mature fibril disassembling with a minimalistic compound, ZPDm. Front Bioeng Biotechnol 2020,8(588947),588947","journal-title":"Front Bioeng Biotechnol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"11897","DOI":"10.1074\/jbc.M113.542340","volume":"289","author":"Herva M.E.","year":"2014","unstructured":"Herva M.E.; Zibaee S.; Fraser G.; Barker R.A.; Goedert M.; Spillantini M.G.; Anti-amyloid compounds inhibit \u03b1-synuclein aggregation induced by protein misfolding cyclic amplification PMCA. J Biol Chem 2014,289(17),11897-11905","journal-title":"J Biol Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1038\/ncomms3575","volume":"4","author":"Bousset L.","year":"2013","unstructured":"Bousset L.; Pieri L.; Ruiz-Arlandis G.; Structural and functional characterization of two alpha-synuclein strains. Nat Commun 2013,4(1),2575","journal-title":"Nat Commun"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/nature14547","volume":"522","author":"Peelaerts W","year":"2015","unstructured":"Peelaerts W; Bousset L; Van der Perren A; \u03b1-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015,522(7556),340-344","journal-title":"Nature"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.chembiol.2018.08.005","volume":"25","author":"Kurnik M.","year":"2018","unstructured":"Kurnik M.; Sahin C.; Andersen C.B.; Potent \u03b1-synuclein aggregation inhibitors, identified by high-throughput screening, mainly target the monomeric state. Cell Chem Biol 2018,25(11),1389-1402.e9","journal-title":"Cell Chem Biol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"9856","DOI":"10.1021\/jm301060g","volume":"55","author":"Van der Veken P.","year":"2012","unstructured":"Van der Veken P.; F\u00fcl\u00f6p V.; Rea D.; P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: Biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy. J Med Chem 2012,55(22),9856-9867","journal-title":"J Med Chem"},{"key":"ref=74","author":"Fischer C","year":"2013","unstructured":"Fischer C; Methot J; Zhou H;  Triazole derivatives for treatment of alzheimer's disease Patent US,8575150 2013","journal-title":"Triazole derivatives for treatment of alzheimer's disease Patent US,8575150"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1039\/D0OB02226H","volume":"19","author":"Maqbool M.","year":"2021","unstructured":"Maqbool M.; Gadhavi J.; Singh A.; Hivare P.; Gupta S.; Hoda N.; Unravelling the potency of triazole analogues for inhibiting \u03b1-synuclein fibrillogenesis and in vitro disaggregation. Org Biomol Chem 2021,19(7),1589-1603","journal-title":"Org Biomol Chem"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"113911","DOI":"10.1016\/j.ejmech.2021.113911","volume":"227","author":"AlNajjar Y.T.","year":"2022","unstructured":"AlNajjar Y.T.; Gabr M.; ElHady A.K.; Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A\/\u03b1-synuclein aggregation inhibitors with neuroprotective effects. Eur J Med Chem 2022,227,113911","journal-title":"Eur J Med Chem"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"3523","DOI":"10.2174\/092986712801323171","volume":"19","author":"Zhou J.","year":"2012","unstructured":"Zhou J.; Chan L.; Zhou S.; Trigonelline: A plant alkaloid with therapeutic potential for diabetes and central nervous system disease. Curr Med Chem 2012,19(21),3523-3531","journal-title":"Curr Med Chem"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000085384","volume":"14","author":"Tohda C.","year":"2005","unstructured":"Tohda C.; Kuboyama T.; Komatsu K.; Search for natural products related to regeneration of the neuronal network. Neurosignals 2005,14(1-2),34-45","journal-title":"Neurosignals"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0014-2999(98)00696-7","volume":"360","author":"Ferger B.","year":"1998","unstructured":"Ferger B.; Spratt C.; Teismann P.; Seitz G.; Kuschinsky K.; Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo. Eur J Pharmacol 1998,360(2-3),155-163","journal-title":"Eur J Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"6873","DOI":"10.3892\/mmr.2018.8700","volume":"17","author":"Zhang Y.","year":"2018","unstructured":"Zhang Y.; Sha R.; Wang K.; Li H.; Yan B.; Zhou N.; Protective effects of tetrahydropalmatine against ketamine-induced learning and memory injury via antioxidative, anti-inflammatory and anti-apoptotic mechanisms in mice. Mol Med Rep 2018,17(5),6873-6880","journal-title":"Mol Med Rep"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"152842","DOI":"10.1016\/j.phymed.2019.152842","volume":"61","author":"Cai C.Z.","year":"2019","unstructured":"Cai C.Z.; Zhou H.F.; Yuan N.N.; Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-proteasome system activation. Phytomedicine 2019,61,152842","journal-title":"Phytomedicine"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7150\/ijbs.23247","volume":"14","author":"Hussain G.","year":"2018","unstructured":"Hussain G.; Rasul A.; Anwar H.; Role of plant derived alkaloids and their mechanism in neurodegenerative disorders. Int J Biol Sci 2018,14(3),341-357","journal-title":"Int J Biol Sci"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.neuint.2015.07.018","volume":"89","author":"Ng Y.P.","year":"2015","unstructured":"Ng Y.P.; Or T.C.T.; Ip N.Y.; Plant alkaloids as drug leads for Alzheimer\u2019s disease. Neurochem Int 2015,89,260-270","journal-title":"Neurochem Int"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jep.2017.12.015","volume":"215","author":"Sahoo A.K.","year":"2018","unstructured":"Sahoo A.K.; Dandapat J.; Dash U.C.; Kanhar S.; Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer\u2019s disease. J Ethnopharmacol 2018,215,42-73","journal-title":"J Ethnopharmacol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"3736","DOI":"10.3390\/molecules26123736","volume":"26","author":"Ghanem S.S.","year":"2021","unstructured":"Ghanem S.S.; Fayed H.S.; Zhu Q.; Natural alkaloid compounds as inhibitors for alpha-synuclein seeded fibril formation and toxicity. Molecules 2021,26(12),3736","journal-title":"Molecules"},{"key":"ref=86","first-page":"e23","volume":"169","author":"Amro M.S.","year":"2018","unstructured":"Amro M.S.; Teoh S.L.; Norzana A.G.; Srijit D.; The potential role of herbal products in the treatment of Parkinson\u2019s disease. Clin Ter 2018,169(1),e23-e33","journal-title":"Clin Ter"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1177\/11779322211050757","author":"Omoboyowa D.A.","year":"2021","unstructured":"Omoboyowa D.A.; Balogun T.A.; Omomule O.M.; Saibu O.A.; Identification of terpenoids from Abrus precatorius against parkinson\u2019s disease proteins using in silico approach. Bioinform Biol Insights 2021,15","journal-title":"Bioinform Biol Insights"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3923\/jpt.2011.580.588","volume":"6","author":"Arora R.","year":"2011","unstructured":"Arora R.; Gill N.S.; Kaur S.; Jain A.D.; Phytopharmacological evaluation of ethanolic extract of the seeds of Abrus precatorius Linn. J Pharmacol Toxicol 2011,6(6),580-588","journal-title":"J Pharmacol Toxicol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S0167-7799(02)02080-2","volume":"20","author":"Raskin I.","year":"2002","unstructured":"Raskin I.; Ribnicky D.M.; Komarnytsky S.; Plants and human health in the twenty-first century. Trends Biotechnol 2002,20(12),522-531","journal-title":"Trends Biotechnol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1126\/science.1096361","volume":"303","author":"Jorgensen W.L.","year":"2004","unstructured":"Jorgensen W.L.; The many roles of computation in drug discovery. Science 2004,303(5665),1813-1818","journal-title":"Science"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1093-3263(03)00123-2","volume":"22","author":"Good A.C.","year":"2003","unstructured":"Good A.C.; Cheney D.L.; Analysis and optimization of structure-based virtual screening protocols (1): Exploration of ligand conformational sampling techniques. J Mol Graph Model 2003,22(1),23-30","journal-title":"J Mol Graph Model"},{"key":"ref=92","doi-asserted-by":"publisher","DOI":"10.21276\/ijcmr.2019.6.11.25","volume":"6","author":"Gupta E.","year":"2019","unstructured":"Gupta E.; Gupta S.R.R.; Kumar A.; Kulshreshtha A.; Niraj R.R.K.; Molecular docking study to identify potent inhibitors of alpha-synuclein aggregation of parkinson\u2019s disease. Int J Contemp Med Res 2019,6(11)","journal-title":"Int J Contemp Med Res"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.ijbiomac.2021.05.071","volume":"182","author":"Rane A.R.","year":"2021","unstructured":"Rane A.R.; Paithankar H.; Hosur R.V.; Choudhary S.; Modulation of \u03b1-synuclein fibrillation by plant metabolites, daidzein, fisetin and scopoletin under physiological conditions. Int J Biol Macromol 2021,182,1278-1291","journal-title":"Int J Biol Macromol"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"112","DOI":"10.9734\/IJBCRR\/2015\/16890","volume":"7","author":"Zhang Y.J.","year":"2015","unstructured":"Zhang Y.J.; Cao N.; Zeng C.M.; Fisetin Prevented Amyloid Formation of Insulin and Attenuated Fibril-induced Cytotoxicity. Int J Biochem Res Rev 2015,7(2),112-120","journal-title":"Int J Biochem Res Rev"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"e0121231","DOI":"10.1371\/journal.pone.0121231","volume":"10","author":"Malisauskas R.","year":"2015","unstructured":"Malisauskas R.; Botyriute A.; Cannon J.G.; Smirnovas V.; Flavone derivatives as inhibitors of insulin amyloid-like fibril formation. PLoS One 2015,10(3),e0121231","journal-title":"PLoS One"},{"key":"ref=96","first-page":"3517","volume":"11","author":"Tyagi N.","year":"2020","unstructured":"Tyagi N.; Shukla R.; Antioxidant drug used in the treatment of reserpin induced Parkinson disease in rats. Int J Pharm Sci Res 2020,11,3517-3528","journal-title":"Int J Pharm Sci Res"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-0-387-46401-5_3","volume":"595","author":"Menon V.P.","year":"2007","unstructured":"Menon V.P.; Sudheer A.R.; Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 2007,595,105-125","journal-title":"Adv Exp Med Biol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"13017","DOI":"10.1007\/s13277-016-5183-y","volume":"37","author":"Kasi PD","year":"2016","unstructured":"Kasi PD; Tamilselvam R; Skalicka-Wo\u017aniak K, et al. Molecular targets of curcumin for cancer therapy: An updated review. Tumour Biol 2016,37(10),13017-13028","journal-title":"Tumour Biol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-0-387-46401-5_8","volume":"595","author":"Cole G.M.","year":"2007","unstructured":"Cole G.M.; Teter B.; Frautschy S.A.; Neuroprotective effects of curcumin. Adv Exp Med Biol 2007,595,197-212","journal-title":"Adv Exp Med Biol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/2211-5463.12372","volume":"8","author":"Krishnamoorthy A.","year":"2018","unstructured":"Krishnamoorthy A.; Tavoosi N.; Chan G.K.L.; Effect of curcumin on amyloid-like aggregates generated from methionine-oxidized apolipoprotein A-I. FEBS Open Bio 2018,8(2),302-310","journal-title":"FEBS Open Bio"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.biochi.2020.01.004","volume":"170","author":"Medvedeva M.","year":"2020","unstructured":"Medvedeva M.; Barinova K.; Melnikova A.; Naturally occurring cinnamic acid derivatives prevent amyloid transformation of alpha-synuclein. Biochimie 2020,170,128-139","journal-title":"Biochimie"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1002\/ptr.5824","volume":"31","author":"Zanyatkin I.","year":"2017","unstructured":"Zanyatkin I.; Stroylova Y.; Tishina S.; Inhibition of prion propagation by 3,4-dimethoxycinnamic acid. Phytother Res 2017,31(7),1046-1055","journal-title":"Phytother Res"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1038\/s41467-018-05971-2","volume":"9","author":"Li B.","year":"2018","unstructured":"Li B.; Ge P.; Murray K.A.; Cryo-EM of full-length \u03b1-synuclein reveals fibril polymorphs with a common structural kernel. Nat Commun 2018,9(1),3609","journal-title":"Nat Commun"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nsmb.3194","volume":"23","author":"Tuttle M.D.","year":"2016","unstructured":"Tuttle M.D.; Comellas G.; Nieuwkoop A.J.; Solid-state NMR structure of a pathogenic fibril of full-length human \u03b1-synuclein. Nat Struct Mol Biol 2016,23(5),409-415","journal-title":"Nat Struct Mol Biol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"116818","DOI":"10.1016\/j.bmc.2022.116818","volume":"66","author":"Han F.","year":"2022","unstructured":"Han F.; Jiang B.; L\u00fc M.H.; Hybrids of polyphenolic acids and xanthone, the potential preventive and therapeutic effects on pd: Design, synthesis, in vitro anti-aggregation of \u03b1-synuclein, and disaggregation against the existed \u03b1-synuclein oligomer and fibril. Bioorg Med Chem 2022,66,116818","journal-title":"Bioorg Med Chem"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"115122","DOI":"10.1016\/j.ejmech.2023.115122","volume":"249","author":"L\u00fc M.H.","year":"2023","unstructured":"L\u00fc M.H.; Wang Z.P.; Xing L.Z.; Hybrids of polyphenolic\/quinone acids, the potential preventive and therapeutic drugs for PD: Disaggregate \u03b1-Syn fibrils, inhibit inclusions, and repair damaged neurons in mice. Eur J Med Chem 2023,249,115122","journal-title":"Eur J Med Chem"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/cmdc.202100147","volume":"16","author":"Sharma R.","year":"2021","unstructured":"Sharma R.; Srivastava T.; Pandey A.R.; Identification of natural products as potential pharmacological chaperones for protein misfolding diseases. ChemMedChem 2021,16(13),2146-2156","journal-title":"ChemMedChem"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406419666230718121644","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/218846\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406419666230718121644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T11:14:01Z","timestamp":1699442041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/218846\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":107,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406419666230718121644","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}